Axovant Has Promise, But Downside Risk Still Outweighs Prospects [Seeking Alpha]
Benitec Biopharma Inc. (BNTC)
US:NASDAQ Investor Relations:
benitec.com/for-investors/investor-faqs
Company Research
Source: Seeking Alpha
Summary Axovant recently failed in Phase II for flagship candidate nelotenserin and decided to discontinue the program. There is still ample promise in its gener therapy programs but they are too premature to generate much shareholder value in the near term. Today's premarket jump higher does not seem sustainable longer term, though investors may want to check in again next year to see where Axovant is by then. Axovant ( AXON ) recently announced that its Phase 2 study of nelotanserin did not meet initial efficacy standards but showed promise on secondary measures. Secondary data was not enough though, and the company decided to discontinue studies and instead concentrate on its gene therapy pipeline. Upon announcement, the stock gapped down from $1.71 to $1.17 and is still sitting at that level after a recent 16% jump on seemingly no news at all. The jump higher is even more surprising considering the company’s recent $30M equity financing
Show less
Read more
Impact Snapshot
Event Time:
BNTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTC alerts
High impacting Benitec Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
BNTC
News
- Benitec Biopharma Inc. (NASDAQ: BNTC) had its price target raised by analysts at JMP Securities from $10.00 to $16.00. They now have a "market outperform" rating on the stock.MarketBeat
- Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study [Yahoo! Finance]Yahoo! Finance
- Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyGlobeNewswire
- Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million [Yahoo! Finance]Yahoo! Finance
- Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 MillionGlobeNewswire
BNTC
Sec Filings
- 4/19/24 - Form 8-K
- 4/18/24 - Form 8-K
- 4/11/24 - Form SC
- BNTC's page on the SEC website